Q-omics provides the consensus-scored RBM43 profile across patient tissues and cancer cell-line models. RBM43 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBM43 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RBM43 RNA expression shows 20,639 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where RBM43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM43 survival associations across molecular data types. RBM43 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM43 RNA expression–survival associations across cancer types. High RBM43 expression shows unfavorable associations in LGG and KICH, but favorable associations in KIRC, SKCM, ESCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBM43 RNA expression.
This table summarizes RBM43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM43 shows lower tumor expression in KICH, UCEC and LUSC and higher tumor expression in KIRC, KIRP and HNSC. The KIRC box plot shows higher RBM43 RNA expression in tumor versus normal tissue (log2 FC = +0.745, t-test p < 0.001).
This table shows molecular features associated with RBM43 in patient tissues and cancer cell lines. In patient samples, RBM43 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
